A collaborative effort across 14 clinical centers in Canada and Australia reports that pregnant women with type 1 diabetes ...

This month marks 80 years since one of the most influential yet underrated inventions burst onto the market in New York on ...

The Global Diabetes Devices Market is projected to expand at a compound annual growth rate (CAGR) of approximately 6% by 2026. Key drivers of this growth include the rising incidence of diabetes, ...

The United States Rapid Acting Insulin Market is poised for significant growth, increasing from US$ 2.32 Billion in 2024 to US$ 3.40 Billion by 2033, with a CAGR of 4.33%. Key growth drivers include ...

The state of California is teaming up with the nonprofit generic drug maker Civica Rx and Biocon Biologics to offer an interchangeable biosimilar insulin glargine pen for $11 beginning January 1, 2026 ...

California Governor Gavin Newsom has announced that the state will start selling affordable insulin in January to help reduce healthcare costs through state-branded drugs. This initiative follows ...

Gov. Gavin Newsom said Thursday that California will begin selling affordable insulin under its own label on Jan. 1, nearly three years after he first announced a partnership to sell state-branded ...

Starting next year, Californians with diabetes will be able to purchase state-branded insulin at steeply reduced prices, Gov. Gavin Newsom announced Thursday, Oct. 16. Long-acting insulin pens will be ...

Gov. Gavin Newsom speaks during a news conference announcing $11 insulin and prescription drugs with the CalRx program inside a Cedars-Sinai pharmacy in Los Angeles on Thursday. The effort is part of ...

California Gov. Gavin Newsom on Thursday announced a plan to offer $11 insulin pens through the state's pharmaceutical venture. Beginning Jan. 1, consumers can purchase a five-pack of pens for a ...